Auritec Pharmaceuticals   Report issue

For profit Phase 1
Founded: Pasadema CA United States (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2015
NCT02431273
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Auritec Pharmaceuticals

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 1)

HIV Infections (Phase 1)

Psoriasis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 4